Tariff Fluctuations Stalled North Carolina Drug Development
Uncertain trade policies impacted long-term investment strategies for the state's top export sector in 2025.
Updated on Oct. 14, 2026 in International Trade
Live Poll
Do you worry that trade tariffs will make your future medical treatments harder to afford?
In 2025, North Carolina saw its pharmaceutical industry face significant market uncertainty due to ongoing tariff policy fluctuations. This instability complicated long-term business decisions for companies relying on trade with key partners Canada and Mexico.
Why it matters
Pharmaceutical firms require stable regulatory environments to manage multi-year development cycles that span 10 to 15 years. Constant shifts in trade status created a volatile marketplace that discouraged investment in essential medical research and development.
Pharmaceuticals held the top position as the number 1 trade commodity in North Carolina in 2025. Bringing a new drug to market typically requires a development timeline of 10 to 15 years.
The players
AbbVie Inc.
This is a global research-based biopharmaceutical company that focuses on developing treatments for chronic and complex conditions.
Genentech
This biotechnology corporation is a member of the Roche Group and specializes in the research and development of medical therapies.
The details
Companies were forced to navigate a landscape where tariff changes prevented consistent capital allocation, often leading investors to redirect funds away from smaller firms. Despite these challenges, major entities continued to commit to the region, with significant expansion and facility announcements occurring throughout the spring of 2025.
Timeline
April 2025: AbbVie Inc. announced a new manufacturing facility in Durham.
May 2025: Genentech announced expansion plans in North Carolina.
2025: Pharmaceuticals were the top trade commodity in North Carolina.
Market Dynamics
This disruption highlights the sensitivity of pharmaceutical innovation to the 10-15 year industry standard for drug development cycles. The volatility marks a departure from the predictable regulatory environments historically required to sustain long-term capital investment in medical research.
The trade uncertainty experienced in 2025 created financial risks for those holding pharmaceutical stocks, particularly in smaller companies prone to capital flight. Retail investors may have faced increased portfolio volatility as manufacturers sought to shift operations overseas to mitigate trade-related costs.
The takeaway
Predictable trade policies are essential for maintaining the continuous funding required for multi-year medical breakthroughs. Investors and patients should monitor trade stability to understand potential future delays in the availability of new treatments.
Further reading
For broader analysis, explore the International Trade section.
Source note: This article includes information reported by Carolina Journal.
Live Poll
Do you worry that trade tariffs will make your future medical treatments harder to afford?
